CTOs on the Move

BioIntervene

www.biointervene.com

 
BioIntervene, Inc. is a preclinical-stage biopharmaceutical company committed to the discovery and development of effective and non-addictive medicines for chronic pain and other chronic inflammatory and neurodegenerative disorders. The Company was founded in 2014 based on insights from research at Saint Louis University and the National Institutes of Health (NIH). BioIntervene`s founding team has pioneered the understanding of adenosine A3 receptor biology, with a focus on developing first-in-class, selective adenosine A3 receptor agonists. California, United States Read more at CB Insights: https://www.cbinsights.com/company/biointervene
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

BioIntervene raised $30M on 01/06/2020

Similar Companies

Uromedica

Uromedica, Inc. is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Optimer Pharmaceuticals

Optimer Pharmaceuticals is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sentigen Biosciences

Sentigen Biosciences is a Phillipsburg, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Melinta

Melinta Therapeutics, Inc. (NASDAQ:MLNT) is the largest pure-play antibiotics company, dedicated to saving lives threatened by the global public health crisis of bacterial infections through the development and commercialization of novel antibiotics that provide new therapeutic solutions. Its four marketed products include Baxdela™ (delafloxacin), Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin), and Minocin® (minocycline) for Injection. It also has an extensive pipeline of preclinical and clinical-stage products representing many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Together, this portfolio provides Melinta with the unique ability to provide providers and patients with a range of solutions that can meet the tremendous need for novel antibiotics treating serious infections.

Kurome Therapeutics

Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms.